The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning of recurrence and metastasis of resectable pancreatic cancer(RPC) and borderline resectable pancreatic cancer (BRPC).
Patients with solid masses (diameter > 1 cm) in the pancreatic area within the accessible range of endoscopic ultrasound, as indicated by clinical symptoms, laboratory tests, and imaging examinations (MRI, CT, B-ultrasound), who require biopsy to clarify the nature of the lesion.
Patients diagnosed with resectable pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer by imaging(CT/MRI).
Newly diagnosed pancreatic cancer patients who have not received radiotherapy or chemotherapy.
Signed informed consent form.
Patients with other active malignant tumors
Patients with coagulation dysfunction (PLT 50,000/mm3, INR > 1.5; roughly estimated, INR > 1.5 is approximately equivalent to PT > 18 seconds)
Pregnant women
Patients with hemorrhagic diseases
Patients with pancreatic cancer from Tongji Hospital, Wuhan, scheduled for ultrasound-guided fine-needle aspiration biopsy
Cohort
Prospective
CTC
Diagnostic testObtaining portal vein blood and peripheral blood from patients, extracting circulating tumor cells (CTCs) therein, and performing CTC sorting, thereby assisting clinical evaluation of the applicability of neoadjuvant therapy and prognostic assessment for patients with potentially resectable pancreatic cancer.
Number of circulating tumor cells in the portal vein
Explore the value of the number of circulating tumor cells in the portal vein in evaluating the applicability of neoadjuvant therapy and guiding treatment decisions for BRPC patients
Subpopulation classification of portal vein circulating tumor cells
Explore the application of portal vein circulating tumor cell subset classification in the prognostic evaluation of neoadjuvant therapy in BRPC patients
Subgroup Classification of Portal Vein Circulating Tumor Cells (PV-CTCs) and Peripheral Blood Circulating Tumor Cells (PB-CTCs)
Explore the differences in subpopulation classification between portal vein circulating tumor cells (PV-CTCs) and peripheral blood circulating tumor cells (PB-CTCs), and investigate their roles in the process of liver metastasis of pancreatic cancer.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
